|
|||||
|
|
||||||
Journal of Clinical Oncology, Vol 26, No 14 (May 10), 2008: pp. 2278-2284 © 2008 American Society of Clinical Oncology. DOI: 10.1200/JCO.2007.13.4528 Utilization and Outcomes of Minimally Invasive Radical Prostatectomy
From the Division of Urologic Surgery; Center for Surgery and Public Health; Division of General Internal Medicine, Brigham and Women's Hospital; Department of Health Care Policy, Harvard Medical School, Boston, MA; and the Abt Associate Clinical Trials, Bethesda, MD Corresponding author: Jim C. Hu, MD, MPH, Division of Urologic Surgery, Brigham and Women's Hospital, Boston, MA 02115; e-mail: jhu2{at}partners.org
Purpose Demand for minimally invasive radical prostatectomy (MIRP) to treat prostate cancer is increasing; however, outcomes remain unclear. We assessed utilization, complications, lengths of stay, and salvage therapy rates for MIRP versus open radical prostatectomy assessed whether MIRP surgeon volume is associated with better outcomes. Methods We identified 2,702 men undergoing MIRP and open radical prostatectomy during 2003 to 2005 from a national 5% sample of Medicare beneficiaries. We assessed the association between surgical approach and outcomes, adjusting for surgeon volume, age, race, comorbidity, and geographic region. Results MIRP utilization increased from 12.2% in 2003 to 31.4% in 2005. Men undergoing MIRP versus open radical prostatectomy had fewer perioperative complications (29.8% v 36.4%; P = .002) and shorter lengths of stay (1.4 v 4.4 days; P < .001); however, they were more likely to receive salvage therapy (27.8% v 9.1%, P < .001). In adjusted analyses, MIRP versus open radical prostatectomy was associated with fewer perioperative complications (odds ratio [OR], 0.73; 95% CI, 0.60 to 0.90), shorter lengths of stay (parameter estimate, –2.99; 95% CI, –3.45 to –2.53) but more anastomotic strictures (OR, 1.40; 95% CI, 1.04 to 1.87) and higher rates of salvage therapy (OR, 3.67; 95% CI, 2.81 to 4.81). Patients of high-volume MIRP experienced fewer anastomotic strictures (OR, 0.93; 95% CI, 0.87 to 0.99) and less salvage therapy (OR, 0.92; 95% CI, 0.88 to 0.98). Conclusion Men undergoing MIRP versus open radical prostatectomy have lower risk for perioperative complications and shorter lengths of stay, but are at higher risk for salvage therapy and anastomotic strictures. However, risk for these unfavorable outcomes decreases with increasing MIRP surgical volume.
One in six men in the United States will develop prostate cancer in his lifetime, and prostate cancer is the second leading cause of cancer mortality in men.1 Radical prostatectomy remains the most common treatment choice in the United States,2,3 accounting for one half of the $1.7 billion spent annually on prostate cancer.4 Presently, men opting for surgery must choose between open and minimally invasive radical prostatectomy with limited data demonstrating differences in outcomes. Although the use of minimally invasive radical prostatectomy has increased in recent years, few data are available about utilization and outcomes compared with open radical prostatectomy. Moreover, while increased surgeon volume is associated with better outcomes for open radical prostatectomy,5,6 there is an absence of data regarding whether volume-outcome effects exist for minimally invasive radical prostatectomy. This is particularly relevant given descriptions of steep learning curves7,8 and increased complications associated with rapid adoption of minimally invasive surgical approaches for other procedures.9,10 To explore utilization and outcomes of minimally invasive radical prostatectomy, we performed a population-based study of Medicare beneficiaries undergoing radical prostatectomy during 2003 to 2005. In particular, we examined whether complications, lengths of stay, and need for salvage therapy were comparable after minimally invasive versus open radical prostatectomy. Furthermore, among men undergoing minimally invasive radical prostatectomy, we assessed whether surgeon volume was associated with better outcomes.
Study Population We identified men 65 years old undergoing radical prostatectomy from a 5% national, random sample of Medicare beneficiaries using administrative data from the Center for Medicare and Medicaid Services (CMS). We excluded men enrolled in health maintenance organizations because their medial claims are not reliably captured by CMS. Men who underwent open (ie, perineal and retropubic radical prostatectomy) and minimally invasive radical prostatectomy from 2003 to 2005 (n = 2,818) were identified from inpatient, outpatient, and carrier component files (formerly Physician/Provider B) based on the presence Physicians Current Procedural Terminology Coding System (fourth edition, [CPT-4]): codes 55810, 55812, 55815 for perineal radical prostatectomy; 55840, 55842, 55845 for retropubic radical prostatectomy; and 55866 for minimally invasive radical prostatectomy.
Dependent Variables
Independent Variables To measure surgeon volume, we determined the number of minimally invasive radical prostatectomies each surgeon had performed during 2003 to 2005 based on our data, which reflects 5% of all procedures performed on Medicare beneficiaries.
Statistical Analysis Multivariate models were constructed to determine the effect of surgical approach, minimally invasive versus open radical prostatectomy, on outcomes of interest while adjusting for age, race, comorbidity, and geographic region. In separate analyses, we also adjusted for open and minimally invasive surgeon volume, which yielded similar results and did not confound the relationship between surgical approach and outcomes (data not shown). Logistic regression was used for perioperative complications, anastomotic strictures, and salvage therapies. The distribution of the length of stay data was unimodal and symmetric with a slight tail. Thus, since the data were approximately symmetric, we estimated a linear regression model using ordinary least squares, a technique robust for estimating linear regression models with symmetric errors, even if the errors are not normally distributed. A second set of multivariate models restricted to minimally invasive radical prostatectomy were constructed to determine the effect of minimally invasive surgeon volume on outcomes while adjusting for age, race, comorbidity, and geographic region. In sensitivity analyses, we repeated analyses after categorizing surgeon volume in tertiles. Results were similar and are not reported. R2 and C (rank correlation index) statistics are reported to provide overall model predictive value for the linear and logistic models, respectively. Because the outcomes of interest from radical prostatectomies performed by the same surgeon may be similar (ie, correlated), we used a robust SE estimate14 for all regression models. Because both age and comorbidity were associated with type of prostatectomy and outcomes, we assessed whether including this interaction in the models influenced the associations between type of prostatectomy and outcomes or between volume of minimally invasive surgeries and outcomes. Inclusion of the interaction terms did not influence any of the relationships of interest; therefore, we present the main effects models only.
Minimally invasive radical prostatectomy increased from 12.2% of all radical prostatectomies in 2003 to 31.4% in 2005 (Fig 1) while retropubic radical prostatectomy decreased from 82.0% to 66.1%, and perineal radical prostatectomy decreased from 5.8% to 2.6% (P < .001). There were no racial or geographic variations in utilization of open versus radical prostatectomy (Table 1); however, men undergoing minimally invasive radical prostatectomy were older (P < .001) and more likely to have multiple comorbid conditions (P = .01).
The unadjusted overall perioperative complication rate for minimally invasive versus open radical prostatectomy was 29.8% versus 36.4% (P = .002), and men undergoing minimally invasive versus open radical prostatectomy had fewer cardiac, respiratory, wound/bleeding, genitourinary, and miscellaneous medical complications (all P < .05; Table 2). Mean length of stay was approximately 3 days shorter for minimally invasive versus open radical prostatectomy (P < .001). Conversely, the rate of anastomotic stricture was 3% higher after minimally invasive versus open radical prostatectomy, although this difference did not reach statistical significance (P = .11).
In adjusted analysis (Table 3), men undergoing minimally invasive versus open radical prostatectomy were less likely to develop perioperative complications (OR, 0.73; 95% CI, 0.60 to 0.90), and experienced shorter lengths of stay (parameter estimate, –2.99; 95% CI, –3.45 to –2.53). However, minimally invasive radical prostatectomy was associated with more anastomotic strictures (OR, 1.40; 95% CI, 1.04 to 1.87) and more salvage therapies within 6 months of surgery (OR, 3.67; 95% CI, 2.81 to 4.81). Multiple comorbidities and older age were significantly associated with perioperative complications, anastomotic strictures, longer lengths of stay, and a greater likelihood of salvage therapy.
In unadjusted analyses among men who underwent minimally invasive radical prostatectomy, we found no association between minimally invasive surgeon volume and perioperative complications (P = .41), lengths of stay (P = .14), or anastomotic strictures (P = .42). However, overall rates of salvage therapy ranged from 40.4% for low volume surgeons to 32.3% for medium and 18.9% for high volume surgeons. Adjusted analysis (Table 4) demonstrated that higher minimally invasive surgeon volume was associated with less salvage therapy (0.92; 95% CI, 0.88 to 0.98) and fewer anastomotic strictures (OR, 0.93; 95% CI, 0.87 to 0.99). The OR for volume can be interpreted as the odds associated with performing 20 more surgeries among Medicare beneficiaries.
For many disease processes, minimally invasive surgery offers distinct, consistently reproducible advantages over open approaches, including shorter hospital stays, fewer inpatient procedures, and lower costs. However, open radical prostatectomy is performed through a relatively small incision that is infrequently associated with significant pain, and relatively short lengths of stay, averaging 1 to 3 days at high volume referral centers.15-18 Nevertheless, many patients intuitively perceive minimally invasive approaches to reduce complications compared with conventional open operations and prefer them due to smaller incisions requiring less analgesics and shorter hospital stays, even at greater cost.19 Some studies suggest that minimally invasive versus open radical prostatectomy results in significantly less blood loss, lower transfusion rates, less use of postoperative analgesics, and quicker convalescence.16,20-22 However, distinguishing hype from reality may be difficult for novel procedures such as minimally invasive radical prostatectomy,22 and the absence of randomized, controlled trials limits the ability to discern differences in open and minimally invasive radical prostatectomy outcomes. Our study has several important findings. First, minimally invasive radical prostatectomy has been rapidly adopted since the initial suggestion of potential advantages over open radical prostatectomy in 2000.23 In contrast to the late 1980s and 1990s when significant geographic variation in open radical prostatectomy utilization and outcomes existed,24,25 minimally invasive radical prostatectomy was adopted uniformly throughout all regions of the United States over our 3-year study period. The trend in diffusion of minimally invasive radical prostatectomy is faster than laparoscopic nephrectomy for donation or cancer control, which comprised less than 10% of all cases 5 years after initial description.26 However, it is slightly less pervasive than laparoscopic cholecystectomy, which accounted for at least 40% of all cases 5 years after initial description.26 Nevertheless, minimally invasive radical prostatectomy is in widespread and rapidly expanding use. Minimally invasive radical prostatectomy was associated with lower perioperative complication rates than open radical prostatectomy. This is noteworthy considering that a greater proportion of men with multiple comorbid conditions and older age underwent minimally invasive versus open radical prostatectomy, and older age and multiple comorbid conditions influence perioperative complications.6,25 Other studies have suggested similar rates of perioperative complications after radical prostatectomy27-29; however, these retrospective, self-reported complications by high volume surgeons primarily focus on genitourinary and surgical complications rather than respiratory and miscellaneous medical complications, which were the leading contributors to overall perioperative complications in our study. Furthermore, comparison of outcomes between reported radical prostatectomy series and different health settings is imprecise due to differences in patient selection and methods of data collection and reporting.22 The use of administrative data may offset these potential biases. The lower perioperative complication rates we observed for minimally invasive radical prostatectomy may be related to procedural blood loss and transfusion rates, which are consistently lower for the minimally invasive versus open surgical approach due in part to the carbon dioxide insufflation pressures used during laparoscopy.16,20-22 Less blood loss lowers the risk of cardiac ischemia and resultant cardiovascular complications, renal insufficiency, and also lessens the risk of respiratory complications that may result from aggressive, compensatory volume expansion. Similarly, intraoperative blood loss is a strong predictor of major complications and death after general and vascular surgeries.30 Men undergoing minimally invasive versus open radical prostatectomy had more than 3 times the odds of receiving salvage therapy (ie, hormone therapy or external-beam radiotherapy) within 6 months of surgery. From 1985 to 1991, 15% of Medicare beneficiaries underwent salvage therapy within 6 months of radical prostatectomy,12 a rate higher than the 9% of men who underwent open radical prostatectomy during 2003 to 2005 in our study, and stage migration may contribute to this difference. According to national guidelines, salvage radiotherapy or hormone therapy should be administered after surgery if prostate specific antigen (PSA) levels fail to reach undetectable levels and or for men with adverse pathologic features and/or positive surgical margins.31 Thus, salvage therapy is a surrogate end point for cancer control. Men undergoing minimally invasive versus open radical prostatectomy were more likely to develop anastomotic strictures, one of the most common complications of open radical prostatectomy, with reported rates ranging from 4% to 32%.11,27,32-34 Strictures negatively impact continence11 and require additional surgery to dilate or incise the scar tissue under general anesthesia, followed by urethral catheterization. In addition, most anastomotic strictures recur and require additional procedures31 that may result in incontinence, requiring placement of artificial urinary sphincter in severe cases.11,17 For minimally invasive radical prostatectomy, the urethrovesical anastomosis is the most technically demanding step for surgeons early in their experience.35 This may explain the lower stricture rate of high volume minimally invasive surgeons in our study. Furthermore, the higher rates of anastomotic stricture and salvage therapy for minimally invasive versus open radical prostatectomy may be due in part to inadequate training and credentialing of practicing surgeons in new minimally invasive techniques.9,10 Similarly, the rapid adoption of laparoscopic cholecystectomy in the United States resulted in the hidden risk of major bile duct injury.9,36 Patients of higher volume minimally invasive surgeons were less likely to experience anastomotic strictures or undergo salvage therapies within 6 months of surgery. A prior case series reported fewer anastomotic strictures associated with greater minimally invasive radical prostatectomy experience.20 Similarly, a retrospective multicenter study demonstrated that greater open surgeon experience was associated with fewer PSA recurrences, presumably due to better open radical prostatectomy surgical technique.37 Authors have described significant learning curves, suggesting that 40 to 150 minimally invasive radical prostatectomies are required to achieve proficiency and outcomes comparable to open radical prostatectomy7,38; yet, a recent survey of urologists found that 37% reported doing fewer than 11 radical prostatectomies per year, while 84% reported doing fewer than 31 per year.39 Consequently, the learning curve may be extended for years.38 Paradoxically, there is no formal certification process and considerable variation exists among hospitals for attaining minimally invasive radical prostatectomy privileges; surgeons may perform the procedure after completing brief courses lasting 2 days or less.35,38 Additional research is needed to assess the impact of minimally invasive radical prostatectomy experience on preservation of urinary and sexual function, for which surgical technique is important.40 Finally, length of stay was approximately 3 days shorter with minimally invasive versus open radical prostatectomy. The duration of the hospital stay is the primary determinant of hospital costs associated with radical prostatectomy,15 and the shorter lengths of stay in addition to lower transfusion rates of minimally invasive versus open radical prostatectomy16,20 may result in cost advantages despite higher intraoperative costs from using disposables and longer operative times.15 However, these minimally invasive cost advantages may only be realized with high surgeon volume,40 shorter operative times,15,17 lower complication rates, and lower rates of salvage therapy.
Limitations Our measures of procedure volume were based on volume within the 5% random sample of Medicare beneficiaries that we studied, and may be measured with some error. Nevertheless, radical prostatectomy surgeon volume for older men enrolled in Medicare, correlates strongly with overall radical prostatectomy surgeon volume.5 We did not examine rates of impotence and incontinence because these are poorly ascertained with administrative data. Moreover, recovery of urinary and sexual function plateau at 18 to 24 months postprostatectomy,44 limiting our ability to detect significant differences over our 3-year study period. Finally, minimally invasive radical prostatectomy included procedures performed with and without robotic assistance because both share a common CPT code. We were therefore unable to distinguish whether the robot was used for assistance during laparoscopy; however, the intraoperative strategy is similar and the prostatic anatomy is by definition identical.45 Several reports suggest that robotic assistance may shorten the learning curve for minimally invasive radical prostatectomy,38,42 but additional research is necessary to determine whether differences in outcomes exist between minimally invasive radical prostatectomy with and without robotic assistance.
Summary
The author(s) indicated no potential conflicts of interest.
Conception and design: Jim C. Hu, Nancy L. Keating Financial support: Jim C. Hu Administrative support: Jim C. Hu, Chris L. Pashos Collection and assembly of data: Qin Wang, Chris L. Pashos, Nancy L. Keating Data analysis and interpretation: Qin Wang, Chris L. Pashos, Stuart R. Lipsitz, Nancy L. Keating Manuscript writing: Jim C. Hu, Stuart R. Lipsitz, Nancy L. Keating Final approval of manuscript: Stuart R. Lipsitz, Nancy L. Keating
The data were de-identified and therefore the research protocol was exempt from institutional review boards. The authors, Jim Hu, Qin Wang, Chris Pashos, Stuart Lipsitz, and Nancy Keating, had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Supported by a Lance Armstrong Young Investigator Award and a Dana Farber/Harvard Cancer Center Career Development Award (J.C.H.); and by an intramural grant by the Brigham and Women's Center for Surgery and Public Health. Authors disclosures of potential conflicts of interest and author contributions are found at the end of this article.
1. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2007. CA Cancer J Clin 57:43-66, 2007 2. Bubolz T, Wasson JH, Lu-Yao G, et al: Treatments for prostate cancer in older men: 1984-1997. Urology 58:977-982, 2001[CrossRef][Medline] 3. Cooperberg MR, Lubeck DP, Meng MV, et al: The changing face of low-risk prostate cancer: Trends in clinical presentation and primary management. J Clin Oncol 22:2141-2149, 2004 4. Gardner TA, Bissonette EA, Petroni GR, et al: Surgical and postoperative factors affecting length of hospital stay after radical prostatectomy. Cancer 89:424-430, 2000[Medline] 5. Begg CB, Riedel ER, Bach PB, et al: Variations in morbidity after radical prostatectomy. N Engl J Med 346:1138-1144, 2002 6. Hu JC, Gold KF, Pashos CL, et al: Role of surgeon volume in radical prostatectomy outcomes. J Clin Oncol 21:401-405, 2003 7. Guillonneau B, Rozet F, Barret E, et al: Laparoscopic radical prostatectomy: Assessment after 240 procedures. Urol Clin North Am 28:189-202, 2001[CrossRef][Medline] 8. Herrell SD, Smith JA Jr: Robotic-assisted laparoscopic prostatectomy: What is the learning curve? Urology 66:105-107, 2005[Medline] 9. Strasberg SM, Hertl M, Soper NJ: An analysis of the problem of biliary injury during laparoscopic cholecystectomy. J Am Coll Surg 180:101-125, 1995[Medline] 10. Denis JL, Hebert Y, Langley A, et al: Explaining diffusion patterns for complex health care innovations. Health Care Manage Rev 27:60-73, 2002[Medline] 11. Park R, Martin S, Goldberg JD, et al: Anastomotic strictures following radical prostatectomy: Insights into incidence, effectiveness of intervention, effect on continence, and factors predisposing to occurrence. Urology 57:742-746, 2001[CrossRef][Medline] 12. Lu-Yao GL, Potosky AL, Albertsen PC, et al: Follow-up prostate cancer treatments after radical prostatectomy: A population-based study. J Natl Cancer Inst 88:166-173, 1996 13. Charlson ME, Pompei P, Ales KL, et al: A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 40:373-383, 1987[CrossRef][Medline] 14. Zeger SL, Liang KY: Longitudinal data analysis for discrete and continuous outcomes. Biometrics 42:121-130, 1986[CrossRef][Medline] 15. Mouraviev V, Nosnik I, Sun L, et al: Financial comparative analysis of minimally invasive surgery to open surgery for localized prostate cancer: A single-institution experience. Urology 69:311-314, 2007[CrossRef][Medline] 16. Menon M, Tewari A, Baize B, et al: Prospective comparison of radical retropubic prostatectomy and robot-assisted anatomic prostatectomy: The Vattikuti Urology Institute experience. Urology 60:864-868, 2002[CrossRef][Medline] 17. Link RE, Su LM, Bhayani SB, et al: Making ends meet: A cost comparison of laparoscopic and open radical retropubic prostatectomy. J Urol 172:269-274, 2004[CrossRef][Medline] 18. Nelson B, Kaufman M, Broughton G, et al: Comparison of length of hospital stay between radical retropubic prostatectomy and robotic assisted laparoscopic prostatectomy. J Urol 177:929, 2007[CrossRef][Medline] 19. Pappas TN, Jacobs DO: Laparoscopic resection for colon cancer: The end of the beginning? N Engl J Med 350:2091-2092, 2004 20. Rassweiler J, Seemann O, Schulze M, et al: Laparoscopic versus open radical prostatectomy: A comparative study at a single institution. J Urol 169:1689-1693, 2003[CrossRef][Medline] 21. Bhayani SB, Pavlovich CP, Hsu TS, et al: Prospective comparison of short-term convalescence: Laparoscopic radical prostatectomy versus open radical retropubic prostatectomy. Urology 61:612-616, 2003[CrossRef][Medline] 22. Smith JA Jr, Herrell SD: Robotic-assisted laparoscopic prostatectomy: Do minimally invasive approaches offer significant advantages? J Clin Oncol 23:8170-8175, 2005 23. Guillonneau B, Vallancien G: Laparoscopic radical prostatectomy: The Montsouris experience. J Urol 163:418-422, 2000[CrossRef][Medline] 24. Lu-Yao GL, McLerran D, Wasson J, et al: An assessment of radical prostatectomy: Time trends, geographic variation, and outcomes–The Prostate Patient Outcomes Research Team. JAMA 269:2633-2636, 1993 25. Hu JC, Gold KF, Pashos CL, et al: Temporal trends in radical prostatectomy complications from 1991 to 1998. J Urol 169:1443-1448, 2003[CrossRef][Medline] 26. Miller DC, Wei JT, Dunn RL, et al: Trends in the diffusion of laparoscopic nephrectomy. JAMA 295:2480-2482, 2006 27. Catalona WJ, Carvalhal GF, Mager DE, et al: Potency, continence and complication rates in 1,870 consecutive radical retropubic prostatectomies. J Urol 162:433-438, 1999[CrossRef][Medline] 28. Guillonneau B, Rozet F, Cathelineau X, et al: Perioperative complications of laparoscopic radical prostatectomy: The Montsouris 3-year experience. J Urol 167:51-56, 2002[CrossRef][Medline] 29. Hu JC, Nelson RA, Wilson TG, et al: Perioperative complications of laparoscopic and robotic assisted laparoscopic radical prostatectomy. J Urol 175:541-546, 2006; discussion 546[CrossRef][Medline] 30. Gawande AA, Kwaan MR, Regenbogen SE, et al: An Apgar score for surgery. J Am Coll Surg 204:201-208, 2007[CrossRef][Medline] 31. National Comprehensive Cancer Network: Clinical Practice Guidelines in Oncology Prostate Cancer. http://www.ncbi.nlm.nih.gov/pubmed/17254923?ordinalpos=7&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum 32. Geary ES, Dendinger TE, Freiha FS, et al: Incontinence and vesical neck strictures following radical retropubic prostatectomy. Urology 45:1000-1006, 1995[CrossRef][Medline] 33. Fowler FJ Jr, Barry MJ, Lu-Yao G, et al: Patient-reported complications and follow-up treatment after radical prostatectomy: The National Medicare Experience: 1988-1990 (updated June 1993). Urology 42:622-629, 1993[CrossRef][Medline] 34. Kao TC, Cruess DF, Garner D, et al: Multicenter patient self-reporting questionnaire on impotence, incontinence and stricture after radical prostatectomy. J Urol 163:858-864, 2000[CrossRef][Medline] 35. Seifert AL, Huntington TR: Laparoscopic radical prostatectomy in a community hospital without robotic assistance. Urology 68:831-833, 2006[CrossRef][Medline] 36. Bernard HR, Hartman TW: Complications after laparoscopic cholecystectomy. Am J Surg 165:533-535, 1993[CrossRef][Medline] 37. Vickers AJ, Bianco FJ, Serio AM, et al: The surgical learning curve for prostate cancer control after radical prostatectomy. J Natl Cancer Inst 99:1171-1177, 2007 38. Ahlering TE, Skarecky D, Lee D, et al: Successful transfer of open surgical skills to a laparoscopic environment using a robotic interface: Initial experience with laparoscopic radical prostatectomy. J Urol 170:1738-1741, 2003[CrossRef][Medline] 39. Denberg TD, Flanigan RC, Kim FJ, et al: Self-reported volume of radical prostatectomies among urologists in the USA. BJU Int 99:339-343, 2007[CrossRef][Medline] 40. Walsh PC: Anatomic radical prostatectomy: Evolution of the surgical technique. J Urol 160:2418-2424, 1998[CrossRef][Medline] 41. Scales CD Jr, Jones PJ, Eisenstein EL, et al: Local cost structures and the economics of robot assisted radical prostatectomy. J Urol 174:2323-2329, 2005[CrossRef][Medline] 42. Menon M, Shrivastava A, Tewari A, et al: Laparoscopic and robot assisted radical prostatectomy: Establishment of a structured program and preliminary analysis of outcomes. J Urol 168:945-949, 2002[CrossRef][Medline] 43. Cooperberg MR, Lubeck DP, Mehta SS, et al: Time trends in clinical risk stratification for prostate cancer: Implications for outcomes (data from CaPSURE). J Urol 170:S21, 2003[CrossRef][Medline] 44. Litwin MS, Melmed GY, Nakazon T: Life after radical prostatectomy: A longitudinal study. J Urol 166:587-592, 2001[CrossRef][Medline] 45. Guillonneau B: Editorial Comment. J Urol 175:546, 2006[CrossRef] Submitted July 11, 2007; accepted January 3, 2008.
Related Editorial
Related Correspondence
This article has been cited by other articles:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||
|
Copyright © 2008 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
|